Neuropace Stock Future Price Prediction

NPCE -  USA Stock  

 21.30  0.22  1.02%

Neuropace stock price prediction is an act of determining the future value of Neuropace shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Neuropace's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Neuropace and does not consider all of the tangible or intangible factors available from Neuropace's fundamental data. We analyze noise-free headlines and recent hype associated with Neuropace, which may create opportunities for some arbitrage if properly timed.
Additionally, see Neuropace Basic Forecasting Models to cross-verify your projections.

Search Price Prediction 

It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Neuropace based on different types of headlines from major news networks to social media. The Neuropace stock price prediction module provides an analysis of price elasticity to changes in media outlook on Neuropace over a specific investment horizon. Using Neuropace hype-based prediction, you can estimate the value of Neuropace from the perspective of Neuropace response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Neuropace. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Neuropace to buy its stock at a price that has no basis in reality. In that case, they are not buying Neuropace because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Neuropace after-hype prediction price

  $ 21.3  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Neuropace in the context of predictive analytics.
LowReal ValueHigh
LowNext ValueHigh
4 Analysts
LowTarget PriceHigh
Estimates (3)
LowProjected EPSHigh
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Neuropace. Your research has to be compared to or analyzed against Neuropace's peers to derive any actionable benefits. When done correctly, Neuropace's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Neuropace.

Neuropace After-Hype Price Prediction Density Analysis

As far as predicting the price of Neuropace at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neuropace or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many smart people who confused the symmetrical distributions of stock prices, such as prices of Neuropace, with the unreliable approximations that try to describe financial returns.
 Next price density 
      Expected price to next headline 

Neuropace Estimiated After-Hype Price Volatility

In the context of predicting Neuropace's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neuropace's historical news coverage. Neuropace's after-hype downside and upside margins for the prediction period are 17.17 and 25.43, respectively. We have considered Neuropace's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4th of August 2021
After-hype Price
Neuropace is not too volatile asset. Analysis and calculation of next after-hype price of Neuropace is based on 3 months time horizon.

Neuropace Stock Price Prediction Analysis

Have you ever been surprised when a price of a company such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neuropace, there might be something going there, and it might present an excellent short sale opportunity.
Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
 0.12  4.13  0.00   0.23  7 Events / Month7 Events / MonthIn about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

Neuropace Hype Timeline

Neuropace is now traded for 21.30. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.23. Neuropace forecasted not to react to the next headlinewith price going to stay at about the same level and average media hype impact volatility of over 100%. The immediate return on the next newsis forecasted to be very small whereas the daily expected return is now at 0.12%. The volatility of relative hype elasticity to Neuropace is about 211.04%. The volatility of related hype on Neuropace is about 211.04% with expected price after next announcement by competition of 21.53. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecastedpress releasewill be in about 7 days.
Additionally, see Neuropace Basic Forecasting Models to cross-verify your projections.

Neuropace Related Hype Analysis

Having access to credible news sources related to Neuropace's direct competition is more important than ever and may enhance your ability to predict Neuropace's future price movements. Getting to know how Neuropace rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neuropace may potentially react to the hype associated with one of its peers.
At Risk
Abbott Laboratories 0.94 9 per month 1.99 (0.0137)  1.93 (1.66)  10.53 
Medtronic 0.39 9 per month 1.17 (0.0462)  1.61 (1.74)  4.30 
Stryker Corp 2.15 9 per month 1.33 (0.0175)  1.83 (1.98)  5.43 
Edwards Lifesciences Corp(0.89) 8 per month 1.01  0.18  2.11 (1.83)  6.09 
Boston Scientific Corp(0.03) 8 per month 0.00 (0.12)  1.64 (2.77)  4.71 
Align Technology 3.07 8 per month 2.02  0.1  2.87 (3.11)  10.04 
Zimmer Biomet Holdings 4.04 8 per month 0.00 (0.18)  2.10 (2.56)  5.24 
Bio-Rad Laboratories 6.72 7 per month 0.97  0.16  2.08 (1.95)  5.13 
Insulet Corp 3.90 8 per month 0.00 (0.05)  3.06 (4.27)  10.07 
Smith Nephew Snats(0.72) 4 per month 0.00 (0.11)  2.30 (3.08)  9.61 

Neuropace Additional Predictive Modules

Most predictive techniques to examine Neuropace price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neuropace using various technical indicators. When you analyze Neuropace charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Neuropace Predictive Indicators

The successful prediction of Neuropace stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neuropace, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neuropace based on analysis of Neuropace hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neuropace's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neuropace's related companies.

Story Coverage note for Neuropace

The number of cover stories for Neuropace depends on current market conditions and Neuropace's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neuropace is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neuropace's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Additionally, see Neuropace Basic Forecasting Models to cross-verify your projections. Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Neuropace Stock analysis

When running Neuropace price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEO Directory
Screen CEOs from public companies around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine Neuropace value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.